109 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
31 May 24
Regulation FD Disclosure
4:21pm
regarding the expected clinical benefits of ImmTAC molecules, including KIMMTRAK, brenetafusp, and the Immunocore’s other product candidates, including … the benefits of the Company’s collaboration with Bristol-Meyers Squibb; and the timing and sufficiency of clinical trial outcomes to support potential
8-K
EX-99.1
IMCR
Immunocore Holdings plc
30 May 24
Other Events
5:22pm
statements. These statements include, but are not limited to, statements regarding the expected clinical benefits of KIMMTRAK; the potential
8-K
EX-10.2
IMCR
Immunocore Holdings plc
28 May 24
Entry into a Material Definitive Agreement
4:17pm
in such Registration Statement or any related prospectus.
2.8. Rule 144 Requirements. With a view to making available to the Investors the benefits
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
, and market share growth; the potential benefits and advantages Immunocore’s products and product candidates, including KIMMTRAK and brenetafusp … ; statements regarding the benefits of the Company’s collaboration with Bristol-Meyers Squibb; the timing and sufficiency of clinical trial outcomes
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
-looking statements include, but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK
DEF 14A
o1zbv6jde 6uh
12 Apr 24
Definitive proxy
4:20pm
424B7
krc9 1glymsqq8d
5 Apr 24
Prospectus with selling stockholder info
4:34pm
PRE 14A
8849r
2 Apr 24
Preliminary proxy
4:45pm
S-3ASR
8o2djvvp1m
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.1
nbpiv5xil
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.2
j8cs 5qhp4
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-10.13
okwziy2vs8v85rxv7d
28 Feb 24
Annual report
7:33am
10-K
EX-97.1
shu7ws63 yhllyxbl
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
rg6nvaokts
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
puzwqn5ocuxg
28 Feb 24
Annual report
7:33am
10-K
irr39ex2
28 Feb 24
Annual report
7:33am
8-K
EX-4.1
10sxoiy4 u7vp0st4d
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
8-K
EX-99.2
xluybzpug hqrchi
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.2
zwh2pvl8jkrgrqb
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.1
j015 ozla93ds
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am